98%
921
2 minutes
20
Hospitalizations can significantly disrupt patient sleep patterns and contribute to insomnia, which places patients at a higher risk of altered mental status as well as other complications. Despite attempts to control environmental factors, deliriogenic medications are often prescribed for the management of hospital-related insomnia. The primary objective of this study is to compare patient-perceived effectiveness of zolpidem versus melatonin in hospitalized patients. All inpatients who received melatonin or zolpidem the previous night as asleep aid and had no acute psychological issues or history of substance abuse were eligible for participation in this single-center, prospective, observational cohort study. The Verran and Snyder-Halpern sleep scale was utilized to evaluate sleep perception in 3 domains: sleep disturbance, effectiveness, and supplementation. A total of 439 patients were screened and 100 patients met study criteria and consented to the study. In the melatonin and zolpidem groups, the estimated adjusted means for the total sleep effectiveness (206.8 mm, 95% confidence interval [CI], 168.7-253.5vs 187.4 mm, 95% CI, 152.8-229.7; =.513), sleep disturbance(362.1 mm, 95% CI, 310.1-422.7 vs 339.54 mm, 95% CI, 290.8-396.4; =.573), and sleep supplementation (111.4 mm, 95% CI, 86.3-143.8 vs 120.9 mm, 95% CI, 94.1-155.2; =.661) domains were not statistically different. Both melatonin and zolpidem were well tolerated with grogginess and headache as the only reported adverse effects. Melatonin demonstrated no significant difference in patient-perceived sleep effectiveness, disturbance, supplementation, or adverse effects when compared to zolpidem.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0897190019851888 | DOI Listing |
J Arthroplasty
September 2025
Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address:
Background: Sleep disturbances are common after total joint arthroplasty (TJA) and are associated with impaired recovery, increased complications, and prolonged hospital stays. Although various pharmacological interventions have been evaluated to improve postoperative sleep quality among TJA patients, consensus on their efficacy and safety remains elusive.
Methods: We conducted a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered the protocol in the International Prospective Register of Systematic Reviews (PROSPERO).
BMC Nephrol
April 2025
NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
Background: Kidney failure is associated with a high symptom burden, yet few studies describe real-world management approaches.
Methods: Kidney care units in Australia, New Zealand (NZ) and the United Kingdom (UK) were surveyed regarding their pharmacological treatment of a range of common symptoms affecting those with kidney failure. The present report describes the results for insomnia, restless legs syndrome (RLS), cramps, and pain.
Psychiatry Clin Neurosci
June 2025
Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan.
Combination therapy with antidepressants and sleep medications is a promising candidate treatment for major depressive disorder (MDD) with insomnia. This systematic review and meta-analysis examined the efficacy and safety of combination therapy with antidepressants and sleep medication for treating MDD with insomnia compared to antidepressant monotherapy by sleep medication class (benzodiazepine, Z-drug, melatonin receptor agonist, and orexin receptor antagonist). This study was preregistered with PROSPERO (CRD42025636571).
View Article and Find Full Text PDFAnn Am Thorac Soc
June 2025
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, Washington.
Many patients with chronic obstructive pulmonary disease (COPD) receive hypnotic prescriptions to mitigate insomnia symptoms. Although clinical practice guidelines advise short-term use, patients often receive these medications on a long-term basis. Because patients with COPD may be more susceptible to adverse effects of hypnotic medication, it is critical that we better understand the incidence and potential influences of this practice.
View Article and Find Full Text PDFSleep Med
April 2025
Psychiatry Unit, Department of Medicine (DAME), University of Udine, Italian Society of Neuropsychopharmacology (SINPF), 33100, Udine, Italy.
Introduction: Current guidelines recommend cognitive behavioural therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia. Pharmacological recommendations by European guidelines for the treatment of insomnia disorder include positive GABAergic modulators such as short and medium acting benzodiazepines and "Z-drugs" (eszopiclone, zaleplon, zolpidem, zopiclone), dual orexin receptor antagonists (DORAs; daridorexant), melatonin receptor agonists (melatonin 2 mg prolonged release - PR). Given the chronic nature of insomnia, the presence of non-responders to some treatments it is often necessary switching between various therapeutic approaches and medications.
View Article and Find Full Text PDF